Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vopimetostat - Tango Therapeutics

Next Previous
Drug Profile

Vopimetostat - Tango Therapeutics

Alternative Names: TNG-462

Latest Information Update: 27 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tango Therapeutics
  • Class Alkanes; Amides; Aminopyridines; Antineoplastics; Benzothiazoles; Ketones; Piperidines; Small molecules
  • Mechanism of Action PRMT5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Soft tissue sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • No development reported Cancer

Most Recent Events

  • 23 Oct 2026 Tango Therapeutics plans a phase III registrational trial for Pancreatic cancer (Combination therapy, First line therapy) in the first half of 2027
  • 22 Oct 2026 Tango Therapeutics plans to submit regulatory applications with the regulatory authorities for Pancreatic cancer (Combination therapy, Second-line therapy or greater)
  • 22 Oct 2026 Efficacy and adverse event data from a phase I/II trial in Non-small cell lung cancer and Pancreatic cancer released by Tango Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top